Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: A randomized study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 1, 1999, Pages 94-96

  Yalçin, Şuayib ^a   Tekuzman, Gülten ^a   Baltali, Eşmen ^a   Özişik, Yavuz ^a   Barişta, Ibrahim ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acute and delayed vomiting; Chemotherapy; Granisetron; Ondansetron; Tropisetron

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANISETRON; METHOTREXATE; ONDANSETRON; SEROTONIN ANTAGONIST; TROPISETRON;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; FEMALE; GRANISETRON; HUMANS; INDOLES; MALE; MIDDLE AGED; ONDANSETRON; PROSPECTIVE STUDIES; SEROTONIN ANTAGONISTS; VOMITING;

EID: 0343570060     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199902000-00023     Document Type: Article

References (15)

1. Coates A, Abraham S, Kaye SB, et al. On the receiving end-patient perception of the side effects of cancer chemotherapy. European Journal of Cancer and Clinical Oncology 1983;19:203-8.
2. Morrow GR. The assessment of nausea and vomiting in clinical oncology: post problems, current issues, and suggestions for future research. Cancer 1984;53:2267-78.
3. Morrow GR, Hickok JT, Rosenthal SN. Progress in reducing nausea and emesis. Cancer 1995;76:343-57.
4. Richardson BP, Engel G, Donatsch P, Stadler PA. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 1985;316:126-31.
5. Andrews PLR, Bhandari P. The 5-hydroxytyriptamine receptor antagonists as antiemetics. Preclinical evaluation and mechanism of action. Eur J Cancer 1993;29A(suppl 1):S11-6.
6. Andrews PLR, Davidson HIM. Activation of vagal afferent terminals by 5-hydroxytryptamine is mediated by the 5-HT3 receptor in the anesthesized ferret [Poster]. J Physiol 1990;422:42.
7. Fiorre JJ, Gralla RJ. Pharmacological treatment of chemotherapy-induced nausea and vomiting. Cancer Invest 1984;2:351-61.
8. Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antogonism. Br J Pharmacol 1986;88:497-9
9. Jones AL, Hill AS, Soukop M, et al. Comparison of dexamethasone and ondansetron in prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991;338:483-7.
10. Bregni M, Siena S, Di Nicola M, Bonadonna G, Gianni AM. Tropisetron plus haloperidol to ameloriate nausea and vomiting associated with high dose alkylating agent cancer chemotherapy. Eur J Cancer 1991;27:561-5.
11. Marty M on behalf of the Granisetron Study Group. A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 1990;26(suppl 1):S28-32.
12. Jantunen IS, Muhonen TT, Kataja VV, et al. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy-a randomised study. Eur J Cancer 1993;29A:1669-72.
13. Mantovani G, Maccio A, Blanchi A, et al. Comparison of granisetron, ondansetron and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer 1996;77: 941-8.
14. Massidda B, Laconi S, Foddi MR, et al. Prevention of non-cisplatin induced emesis: role of the antagonists of 5HT3 receptors [abstract]. Ann Oncol 1994;5(suppl 8):S204.
15. Gralla RJ. Antiemetic treatment for cancer chemotherapy: problems and progress. Support Care Cancer 1994;2:275-6.